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Abstract 
Background 
Antiretroviral therapy (ART) recommendations among HIV – infected pregnant women have 
been revised several times by the World Health Organization (WHO). Option B+, which is the 
latest recommendation continues to be rolled out in several countries across the globe but mostly 
in sub-Saharan Africa. Retention in care and adherence to antiretroviral (ARV) drugs taken by 
these women remains unclear in this new program. We assessed ability to stay in care (retention) 
and adherence to ART among HIV – infected women starting life-long treatment during 
pregnancy and after, at an HIV care and treatment clinic in Ifakara Tanzania. Our study provided 
an opportunity to understand the trends in adherence to ART and retention in care for this 
population. 
Methods 
We analyzed data of HIV-infected pregnant women registered and starting ART for the first time 
in the Kilombero and Ulanga Antiretroviral Cohort in 2009 and 2010 with a follow up period of 
up to two years to 2011 and 2012 respectively. Adherence was by patient self-report (PSR) and 
was sufficient (good) if the woman took all the prescribed pills of the issued batch or insufficient 
(poor) if she missed two or more pills. Women that missed two or more consecutive scheduled 
visits to the clinic were not retained while those that honored their scheduled visits were retained 
in care. Two sample t test and Wilcoxon rank sum test were used to test predictor outcome 
associations for continuous variables while Pearson’s and Fisher’s exact tests were used for 
categorical ones. Hazard ratios of each predictor variable were calculated using Cox regression. 
 Student No: 737395                                                                                                                                       Page v 
 
Results 
A total of 1,282 HIV – infected women were registered in KIULARCO between 2009 and 2010. 
Fifty (50) were pregnant and started life-long ART upon registration in this period. Of these, 25 
(50%) were registered in 2009 and the other 25 (50%) in 2010. Slightly more than half, 52.2% 
had CD4 cell counts above 350cells/mm3. Almost half, 49% of the women were registered in 
their final (third) pregnancy trimester. About 82% were in WHO stage one and 60% of all the 50 
women were initiated on AZT/3TC/EFV regimen. Only 5.7% had secondary education while the 
rest had primary or no education at all. Of the women that reported their partners HIV state, 
54.5% had partners that had never tested for HIV.  
Adherence for all participants was reported as sufficient (good) for the entire period the women 
were in care. No one had insufficient (poor) adherence. Retention in care was higher during 
pregnancy than after delivery. Generally, loss to follow up was 40%. About 30% were lost 
during pregnancy and the majority, 70% lost after they had delivered their babies. There was no 
evidence to prove that any of the factors studied independently predicted non retention. The most 
likely time to non retention was six months after delivery. 
Conclusions 
Our study, despite small sample size, shows that among women diagnosed HIV – infected and 
starting life-long ART during pregnancy (Option B+), adherence to ART is sufficient and 
retention in care similar during and after pregnancy. Counseling on the importance of staying in 
care especially around the first few months after delivery should be emphasized at ANC. 
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Chapter One: Introduction 
Background 
Adherence to antiretroviral therapy (ART) and retention in care among persons living with HIV 
(PLHIV) started on this life-long treatment are very important in curbing the mortality and 
morbidity registered in this population [1]. By the end of 2011, approximately 34 million people 
were living with HIV [1]. Sub-Saharan Africa contributes to 69% of this global burden with the 
majority (58%) being women[1]. Many of these women are getting or will get pregnant at some 
point while they’re HIV infected.  
Due to overwhelming evidence that ART among HIV- infected pregnant women prevents 
transmission of HIV to the un-born babies [2, 3] the need to emphasize adherence to ART and 
retention in care for these women is highly important. This is the only way to achieve proper 
treatment outcomes [4-6]. More so, even if they don’t get ART for prevention of mother to child 
transmission of HIV (PMTCT) they will need it for their own health when the CD4 cell counts 
drop [7]. 
In an effort to get more and more pregnant women to know their HIV status, several countries 
have implemented a number of pregnant women targeted testing strategies and approaches [8]. 
One of these strategies is routine HIV testing to all pregnant women attending ante-natal care 
(ANC) clinics [8, 9]. Women coming to attend ANC services and have a negative HIV test result 
more than three months prior to the current visit or are not aware of their HIV serostatus are 
offered an HIV test [9]. 
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Tanzania is one of the countries that have embraced this strategy [10].  This integration of HIV 
testing into ANC services has led to an increased number of newly diagnosed HIV-infected 
pregnant women and several of them are eligible to start antiretroviral treatment [10]. The 
current WHO recommendations for PMTCT state that every woman diagnosed HIV – infected in 
pregnancy starts life-long ART [5, 11]. Adherence to ART and retention in care after treatment 
initiation is crucial among this population since both insufficient (poor) adherence and none 
retention in care can lead to drug resistance [12], sicker states and several other undesirable 
treatment outcomes [13, 14]. HIV-infected pregnant women starting ART may also not be able 
to protect the babies in the subsequent pregnancies [11, 13] if adherence to treatment and 
retention in care are not addressed. 
The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) is run by the Chronic Diseases 
Clinic of Ifakara (CDCI) at St. Francis referral hospital (SFRH). Care and treatment of HIV-
positive patients is provided at SFRH according to the National Aids Control Program (NACP) 
through the CDCI. SFRH is the most important health care facility in Kilombero and Ulanga 
districts, in the Morogoro region of southern Tanzania. The CDCI, a clinic with-in the hospital, 
works in cooperation with the Ifakara Health Institute (IHI), the Swiss Tropical and Public 
Health Institute and the Department of Infectious Diseases and Hospital Epidemiology of the 
University Hospitals of Basel and Bern, Switzerland. Since late 2004, all HIV-infected patients 
attending the CDCI are asked for informed consent to be enrolled in the Kilombero and Ulanga 
Antiretroviral Cohort (KIULARCO). This cohort comprises more than 6,000 people living with 
HIV (PLHIV) and is the largest rural HIV cohort in Tanzania [15]. This offers an opportunity to 
study the intended outcomes among HIV-infected pregnant women starting life-long treatment. 
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Statement of the problem 
In order to maximize the benefit of starting ART, PLHIV must be retained in care to ensure 
regular follow up that enables clinical monitoring of CD4 counts and viral loads and good drug 
adherence [3, 4, 16]. 
Unfortunately, adherence and retention rates among PLHIV are still low [1]. The Centers for 
Disease Control estimates that only 56% of all PLHIV linked to care are retained [1]. Worse still, 
to our knowledge, evidence on adherence and retention in care including predictors of these two 
outcomes among HIV-infected pregnant women starting ART is lacking.  
Justification of the study 
The results from this study would allow for a better understanding of which period (during 
pregnancy or afterwards) HIV-infected pregnant women starting ART are at risk of poor 
adherence and loss to follow up.  
Furthermore, the assessed predictive factors of adherence to ART and retention in care would 
allow us to know determinants of adherence to ART and retention in care for this population and 
as such offer a basis for potential counteractive measures to mitigate these problems. 
Assessing adherence to ART and retention in care among HIV-infected pregnant women starting 
life-long treatment would also offer a concise understanding of the adherence and retention 
trends in this population. This makes Option B+ and other ART programs among HIV – infected 
pregnant women significantly improve PMTCT outcomes, women livelihoods and curtail 
transmissions from the women to their sexual partners.  
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Literature review 
HIV burden  
By the end of 2011, approximately 34 million people across the globe were living with HIV [1]. 
Majority of these (69%) were in Sub-Saharan Africa [1] with the bigger proportion of them 
(58%) being women. With such huge numbers of infected women, unborn babies are prone to 
HIV if nothing to prevent the infection is done [4]. This in turn leads to more new infections. 
ART among pregnant women 
For over a decade, several studies have shown that using ART during and after pregnancy is 
effective in preventing MTCT of HIV [2, 3, 17].   
Since the release of the first guidelines on PMTCT, the World Health Organization (WHO) has 
published several revisions and updates [1, 5, 11]. New evidence supporting safety and 
effectiveness of antiretroviral (ARV) drugs among pregnant women [14, 16, 18], the increase in 
availability of drugs [1, 19], the decrease in cost [19] and the ambitious goals of elimination of 
pediatric HIV infection by 2015 have driven this constant change in guidelines [4]. 
In 2010, WHO issued PMTCT guidelines recommending two PMTCT options; Option A and 
Option B [6, 20]. These two options include both treatment and prophylaxis components. In both 
options, CD4 cell count is necessary to decide the eligibility of HIV-infected pregnant women 
for life-long ART. For all women who have CD4 ≤ 350 cells/mm3 initiation of lifelong ART is 
recommended [20]. For those women not eligible for lifelong ART, Option A recommends 
antenatal prophylaxis with zidovudine followed by intrapartum and postpartum prophylaxis with 
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single doze nevirapine and zidovudine plus lamivudine [6]. Option B recommends triple ARV 
prophylaxis until after finishing breastfeeding [20].   
The most recent WHO PMTCT recommendation is Option B+ [5, 11]. This option advocates for 
initiation of life-long ART to all HIV-infected pregnant women regardless of CD4 count and 
clinical stage and administration of daily nevirapine or zidovudine to all HIV exposed infants 
until the age of 4 to 6 weeks regardless of the breast-feeding method [5, 11]. 
PMTCT Guidelines in Tanzania 
The first Tanzanian PMTCT guidelines were developed in 2004 [21]. In 2007, the Tanzania 
Ministry of Health revised them and moved from single dose nevirapine (sdNVP) to combination 
prophylaxis [22]. In June 2012, new guidelines recommending the WHO PMTCT Option A were 
published [22]. Option B+ was not standard of care among pregnant women in Tanzania during 
our study period. 
Adherence to ART 
Sufficient (good) adherence to ART during pregnancy and postpartum contributes to improved 
livelihoods and good PMTCT outcomes among women  [14]. Some studies [23, 24] including a 
systematic review and meta-analysis [25], have assessed adherence to ART among pregnant and 
breastfeeding mothers. However, most of these studies follow up the participants until six 
months postpartum. During this period, mothers are supposed to be highly motivated to protect 
their child from MTCT. Moreover, during the first year after delivery, mothers and infants will 
attend the health facilities to get the scheduled immunizations [26].  
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These two reasons might be driving factors to keeping them adherent and retained in care [26]. 
An extended follow-up period such as done by the Mitra Plus study in Tanzania [27] and another 
study in Malawi [28] offers a better chance to understand adherence patterns in this population.  
Since the final infant’s HIV serostatus is often known at 18 months [11] and all immunizations 
are completed by a year [29], adherence trends studied after this period will surely be due to the 
woman’s own drive and willingness to get treatment for her own health and not for PMTCT [26]. 
The determinants of adherence trends observed are also less influenced by the child’s scheduled 
clinic visits. 
Retention in Care 
Retention in care offers HIV-infected people a chance to be seen and continuously monitored by 
health care providers contributing to improved treatment outcomes [11]. Among HIV – infected 
pregnant women, the monitoring contributes to improved PMTCT outcomes both during and 
after pregnancy [5, 30]. Non retention in care in Sub-Saharan Africa occurs both in pre ART and 
post ART initiation periods [28]. Some studies have registered rates of loss to follow up ranging 
from 30% to 50%, [27]. Non retention in care among HIV- infected pregnant women has only 
been studied recently in South Africa [31] with 57.5% lost between HIV testing in pregnancy 
and six months post delivery. The study however, included pregnant women eligible and non-
eligible to start ART. Our study focuses on women starting life-long ART, so to understand 
better this outcome in such a population. 
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Determinants of adherence to ART and retention in care 
Factors determining adherence to ART or retention in HIV care are either socio-demographic or 
related to the system through which HIV care and treatment is provided [11].  
Age, sex, race, education status, marital state, domestic violence and economic status have been 
observed in several studies as socio-demographic determinants of adherence to ART and 
retention in care among PLHIV [31, 35, 36].  
The distance to the HIV care and treatment clinic, transport costs, drug stock outs and late 
procurement by specific clinics have also influenced the adherence and retention patterns among 
HIV- infected people [36].  
The factors above have all been studied in general populations and not specifically among HIV- 
infected pregnant women. A study like ours, will clarify whether these factors determine 
adherence and retention in care for this population as well. 
Summary: 
There is a high global HIV burden and infection rates are higher among women than men. The 
advent of ART use in pregnancy has reduced several new infections to un-born babies through 
recommendations by WHO like Option B+.  
Understanding adherence to ART and retention in care trends for HIV- infected pregnant women 
starting life-long ART has the potential to improve Option B+ and HIV treatment success among 
care and treatment programs. This will save many lives of babies, improve livelihoods of their 
mothers and reduce transmissions to their sexual partners. 
 Student No: 737395                                                                                                                                       Page 8 
 
Aims and Objectives 
Research Question 
To understand public health implications of starting life-long ART among HIV infected pregnant 
women, we explored the questions. 
 Is there a difference in adherence to ART during pregnancy and during two years after 
delivery among HIV-infected pregnant women starting life-long treatment at Ifakara 
between 2009 and 2010? 
 Is there a difference in retention in care during pregnancy and during two years after 
delivery among HIV-infected pregnant women starting life-long treatment at Ifakara 
between 2009 and 2010? 
 What factors are associated with adherence to ART and retention in care among HIV-
infected pregnant women starting life-long treatment at Ifakara between 2009 and 2010? 
Study Aim 
This study sought to establish whether there is a difference in adherence to ART and retention in 
care with associated factors during pregnancy and at two years after delivery among newly 
diagnosed HIV-infected pregnant women starting life-long treatment at Ifakara between 2009 
and 2010. 
 
 
 Student No: 737395                                                                                                                                       Page 9 
 
Study Objectives 
1. To compare adherence to ART during pregnancy and during two years after delivery 
among newly diagnosed HIV-infected pregnant women started on ART enrolled in 
Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) between 2009 and 2010. 
2. To compare retention in HIV care during pregnancy and during two years after delivery 
among newly diagnosed HIV-infected pregnant women started on ART enrolled in 
KIULARCO between 2009 and 2010. 
3. To estimate time to none retention among newly diagnosed HIV-infected pregnant 
women enrolled in KIULARCO starting ART between 2009 and 2010. 
4. To determine factors associated with adherence among newly diagnosed HIV-infected 
pregnant women started on ART enrolled in KIULARCO between 2009 and 2010. 
5. To determine factors associated with retention in care among newly diagnosed HIV-
infected pregnant women started on ART enrolled in KIULARCO between 2009 and 
2010. 
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Chapter Two: Methodology 
Introduction 
This chapter elaborates the study methods used for the study right from the design and explains 
in detail the study setting of the Chronic Diseases Clinic of Ifakara (CDCI) at St. Francis referral 
hospital (SFRH).  The chapter further explains the Kilombero and Ulanga ART cohort and how 
clients including pregnant women got enrolled. The population studied, together with the 
inclusion and exclusion criteria are explicitly laid out together with proper definition of retention 
in care and adherence to ART. Common methods of adherence and retention measurement are 
explained in depth and the chapter ends with a precise explanation of how the data was cleaned 
and analyzed to generate the results presented in this research report. 
Study design 
This study was a secondary analysis of data that was collected longitudinally among participants 
attending the CDCI and being enrolled in the Kilombero and Ulanga Antiretroviral Cohort.  
Study setting 
Pregnant women attend antenatal care (ANC) at the reproductive and child health clinic (RCHC) 
in SFRH. All women attending ANC services whose serostatus is unknown or had a negative test 
result more than 3 months prior to the visit are offered an HIV test. HIV-infected women 
diagnosed in the RCHC are referred to the CDCI for HIV care and treatment. 
At the CDCI, HIV-infected pregnant women are counseled, CD4+ cell count is done and a 
baseline clinical visit with an HIV clinician takes place. HIV-infected pregnant women eligible 
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to start ART according to the national guidelines of the NACP are started on ART and 
subsequently followed up.  
After initiation of ART, women are scheduled for clinical visits, drug refill and laboratory 
monitoring. Also, in case they present with any complaint, they attend the CDCI to be reviewed 
by a clinician (un-scheduled visits). Every time a woman is seen by the clinician, a detailed 
health history, pregnancy status and adherence are assessed and filled in a follow-up form. Blood 
samples are drawn during the follow-up period for subsequent CD4+ cell count and other organ 
function monitoring.  
Study population 
We studied women that were diagnosed HIV positive registered in KIULARCO and started on 
ART during pregnancy between January 2009 and December 2010. All these women came from 
Kilombero and Ulanga districts in the Morogoro region of southern Tanzania. 
Inclusion criteria 
 Newly diagnosed HIV-infected pregnant women starting life-long ART according to the 
Tanzanian NACP guidelines enrolled in KIULARCO between 2009 and 2010.  
 Newly diagnosed HIV-infected pregnant women that without meeting the CD4 and WHO 
stage criteria to start ART were willing to and were started on life-long ART enrolled in 
KIULARCO between 2009 and 2010.  
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Exclusion criteria 
 Newly diagnosed HIV-infected woman and not pregnant 
 Newly diagnosed HIV –infected pregnant women and not started on life-long ART 
during pregnancy. 
 Women previously diagnosed HIV-infected but currently pregnant. 
Outcome measurements 
Adherence to ART 
Adherence to ART for this study was defined as taking the prescribed pills in the right amount. 
We used the patient self-report (PSR) method which allows the participant to recall the pills 
taken and missed for the last issued batch. This method of assessment has been used in other 
studies and proved to be an effective tool of measuring adherence [32, 33]. 
It was dichotomized into two different measures as; sufficient (good) and insufficient (poor) 
adherence [12, 25]. Insufficient (poor) adherence was missing two or more days without taking 
ART of the last issued batch. If a woman missed less than 2 days without taking ART of the last 
issued batch, she was deemed to have sufficient (good) adherence to treatment. This information 
in the dataset formed our assessment to adherence levels during pregnancy and at 2 years after 
delivery.  
Retention in care 
One was either in care or not at any point during the study period. Retention in care was 
honoring every scheduled clinic visit to the CDCI for two years from the date registered. Those 
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not retained in care were participants that had missed attending two or more consecutive 
scheduled visits to the clinic. We censored as being in care, all those that made two years in the 
cohort since registration. Women not meeting this criterion were censored as not retained in care. 
The dataset records were assessed on whether the woman honored scheduled visits to the CDCI 
and this provided basis for assessment of retention in HIV care. These numbers were compared 
for the two time periods; during and after pregnancy.  
Exposure measurements 
The primary exposure variable was the period when the woman was pregnant and after 
pregnancy. The period during pregnancy spanned from the time of registration into the cohort 
until delivery while the period after pregnancy stretched from delivery to the mark of two years 
of follow up (at two years after delivery). The secondary exposure variables for this research 
were:- 
Socio-demographic variables 
 Age at the time of registration was measured in years and was categorised during analysis 
to find out if specific age bands had different trends in respect to the two studied 
outcomes among the study group. 
 Level of education was taken to be none; if a woman had never gone to school, primary; 
if she had gone to primary school but not secondary school and higher; if she attended 
secondary school or any  tertiary institution or both. 
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 The year of registration was a factor we also considered in this research. Women were 
registered over two years from 2009 to 2010 but had to have a follow up of up to 2 years 
by 2012. This excluded those registered in 2011 and 2012. 
 Parity was the number of living children that the mother reported to have at registration. 
 Disclosure of HIV status. Women were asked if they had disclosed to anyone their HIV 
status.  
 Marital status.  Women were asked if they were single, married, divorced or separated. 
The ones that were divorced or separated were put in the same category as the single.  
 Gestation age at registration. Women were asked for their last normal menstrual period 
and gestation of the current pregnancy calculated. This was recorded as weeks but for our 
analysis it was changed to months. 
 Partner tested. Women were asked if their partners had been tested for HIV to find out if 
their being sero-negative or positive for HIV affected the woman’s outcome. 
 Occupation. Source of income was farming, employment in government and employment 
in private sector. Women that were employed in the both government and private sectors 
were considered non-farmers. 
Clinical variables 
 CD4 cell counts were measured at baseline and at subsequent follow-up visits when the 
clinician wanted to monitor response to ART. The measurement was done in cells/mm3. 
We used baseline CD4 counts and categorised them into >350 cells/mm3 or below to 
ascertain their relation to the two outcomes of interest. 
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 WHO stage at registration was the baseline WHO stage of the woman. It was classified 
according to the WHO classification as 1, 2, 3 or 4 [34] 
 Any opportunistic infection  
 ART regimen was the type of combination antiretroviral drugs the woman was started on. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Follow-up patterns in the Cohort 
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Data management and statistical analysis 
The collected information on the baseline and follow-up forms and the laboratory results are 
double entered into the KIULARCO database. This is done by trained data entry clerks 
supervised by a data manager.  
Data cleaning and management 
A dataset was provided containing de-identified particulars, baseline and follow-up information 
of participants that had been enrolled in KIULARCO from 2004 to 2012. Using Stata TM 
statistical package, we checked and cleaned firstly the participant registration dates for duplicates 
and missing dates among those that had a pregnancy ever reported. The observations that had 
registration date missing and had no pregnancy reported were dropped together with all those 
registered before January /1 /2009 (Study Period start). We also generated year of registration 
without month or day for each participant from their respective date of registration.  
Participant’s gender was checked for missing information at all follow-ups but also to filter out 
any mixed gender on subsquent visits. We dropped observations of all males in the data set since 
our study was on females.  
Duplicates in the participant baseline and follow-up forms were deleted and follow-up numbers 
generated for every follow-up observations in ascending order according to the date the 
participant visited the clinic.  
We coded 1 if a woman had a pregnancy ever reported either at baseline or any follow-up visit 
observation and code 2 if a woman had no observation during follow-up with pregnancy 
reported. Those with no pregnancy ever reported at any visit during follow up were dropped 
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from the dataset. Among those that had a pregnancy ever reported at anytime during follow-up, 
we retained women that were pregnant at registration into KIULARCO and dropped the ones 
that were not pregnant by the time of registration and only got pregnant later during follow-up. 
They were dropped because they got pregnant during care but were not pregnant at registration. 
Among women that were pregnant at registration, we kept those that started ART during that 
pregnancy and dropped the ones that didnot start ART while pregnant. 
To be able to analyze time to non-retention, censoring occurred at two years since registration. 
This was 2011 for those registered in 2009 and 2012 for those registered in 2010. Participants 
that didn’t get to two years either through death, transfer out, lost or any other means, were 
considered to have the event of interest (not retained). This censoring generated the woman’s 
status at follow up as either retained in care if she had follow up visits up to two years since 
registration (censored) or not retained in care if  her last visit didn’t go up to two years since 
registration into the cohort (event). We also generated total length of follow-up (time) in months 
by subtracting the last date at censoring from the registration date in the cohort. 
Statistical analysis 
Descriptive statistical analysis 
We assessed for normality in distribution of all continuous variables like age and CD4 counts 
using skewness and kurtosis tests, normal quantile plots, normal probability plots and normal 
distribution histogram graphs.  
Normally distributed baseline continuous characteristics were summarized to obtain their means 
together with the standard deviation. We also tested for association of these characteristics with 
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the outcome variables by running the parametric; two sample t test to accord presence or lack of 
associations. 
Continuous variables that were not normally distributed like mothers’ baseline CD4 counts were    
summarized to obtain their median together with the inter-quartile range. We also tested for 
association of these characteristics with the outcome variables by running the non-parametric; 
Mann-Whitney test (Wilcoxon rank sum) to accord presence or lack of associations.  
We carried out two way tabulations of frequencies of categorical baseline characteristics using 
Pearson’s Chi Square test and Fischer’s Exact test where observations of any cell were sparse. 
Proportions of mothers in each category with the respective percentages (%) were obtained.  
Inferential statistical analysis  
Kaplan Meier estimates were used to compare retention in care between the two periods. The log 
rank test for equality of survival functions was used to test for statistically significant differences 
in retention in care between these two periods at the 5% level of significance. From Pearson’s 
Chi Square, Fisher’s exact, Mann-Whitney and two sample t tests, baseline characteristics that 
were found significantly associated with retention in care were fit in univariable Cox regression 
models to ascertain the strength of association. This was also done for baseline characteristics 
that were not significantly associated with retention in care but had biological or sociological 
plausibility. Hazard ratios and their respective 95% confidence intervals were generated.  
Baseline exposure characteristics that generated associations with outcomes and had a P value 
less than 0.1 at univariable Cox regression were fit into multi-variable Cox regression analysis 
models. Biologically and sociologically plausible characteristics were also included in the multi-
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variable Cox regression models to determine if they were independent predictors of retention in 
care. 
Person time for participants was determined from the day of registration into the cohort to the 
date censorship. Kaplan Meier survival estimate curves were plotted to depict the median time to 
non-retention. Non-retention rates were generated for the two periods after survival time setting 
the data. 
Confounding and interaction between starting ART in pregnancy and retention in care was also 
tested. The categorical variables were stratified and Mantel-Hanzsel odds ratios determined. 
Baseline characteristics that caused a change of less than 10% had strata specific odds ratios 
assessed for similarity or difference to rule out confounding.  
We were unable to run model diagnostics for the assumptions of linearity and equal proportions 
because there was no evidence to show that the factors modeled explained retention in care. 
Ethical considerations 
The KIULARCO project obtained ethical clearance from the IHI Ethical Review Board and the 
National Institute for Medical Research from Tanzania.  
Permission to use the KUILARCO dataset for this research was obtained from the management 
of IHI and CDCI in Tanzania.  
Ethics clearance to carry out the research was approved by the University of the Witwatersrand 
human research ethics committee (medical). 
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Chapter Three: Results 
Introduction 
In this chapter, we detail the results of the study. From the accrual of total numbers of pregnant 
women studied to the qualities of their baseline socio-demographic and clinical characteristics. 
The chapter explains in detail the differences in retention in care both during pregnancy and after 
pregnancy, elaborating clearly the evidence generated towards ascertaining predictors of non-
retention. The time to non-retention together with adherence trends are made mention of. 
Study participants 
In 2009 and 2010, a total of 2,016 HIV positive clients were registered into KIULARCO. The 
number of males was 734 while females were 1,282. Of these females, 836 women were 
registered between January and December 2009 while between January and December 2010, 446 
women were registered. Out of 1,282 women registered in the two years, 106 (8.3%) women had 
a pregnancy within two years of follow up since registration into the cohort. The remaining 
1,176 (91.7%) women did not get pregnant within the 2 years of follow up since registration into 
the cohort. As shown in the figure 1 below, 55 (51.9%) of the total 106 pregnant women were 
pregnant at the time of registration into the cohort. The remaining 51 pregnant women (48.1%) 
got pregnant much later after registration into the cohort i.e.; got pregnant while already in care. 
Five women (9.1%) of the 55 women pregnant at the time of registration didn’t start ART during 
pregnancy. The 50 women (90.9%) that started ART while still pregnant were the sample that 
met the inclusion criteria for the study. 
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Figure 2: Consort diagram showing the accrual of number of study participants. 
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Baseline characteristics 
The proportions, means and medians of socio-demographic and clinical characteristics of study 
participants at the time of registration are summarized in table 1 below.  
Our results show that 25 (50%) of the women were registered in 2009 while the other 25 (50%) 
were registered in 2010. Women registered in 2009 and 2010 were followed up until 2011 and 
2012 respectively. 
The mean age at registration was 29 years with a standard deviation of 6 years. Baseline CD4 
cell counts were documented for 46 women. Twenty two women (47.8%) had CD4 cell counts 
less or equal to 350 cells/mm3 at registration while 24 women (52.2%) had CD4 cell counts 
more than 350 cells/mm3.  
AZT/3TC/EFV was the most prescribed ART regimen with 30 women (60%) initiated on it. Ten 
women (20%) were initiated on d4T/3TC/NVP, 3 women (6%) on AZT/3TC/NVP and 7 women 
(14%) on other ART combination regimens. The majority of women were in WHO stage 1 (41 
women 82%). Those in WHO stage 2 were 5(10%), while the ones in WHO stage 3 were 2(4%). 
Only 2(4%) women were in WHO stage 4.   
Almost half of the total number of women had been registered in their third trimester of 
pregnancy (24 women 49%). The women in the second trimester at the time of registration were 
11(22.4%) and 14 (28.6%) were in the first trimester at the time of registration. Eleven women 
(29.7%) had no child while 26 women (70.3%) had either one or more children at registration. 
Thirty six women (72%) had disclosed their HIV status to either their partner or someone else 
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and 14 (28%) had never disclosed their HIV status to anyone. Thirty two women (80%) of the 40 
women that reported their marital status were married while the rest were single. 
Only 9 women (18.4%) of the 49 women that had answered the alcohol intake question had a 
history of alcohol use. Among the 35 women whose education status was recorded in the dataset, 
28 (80%) had attained primary school level of education, 2 women (5.7%) had secondary school 
level of education and 5 women (14.3%) had no school education at all. Occupation status was 
recorded for 33 women of whom 31 (94%) were farmers. The 2 women (6%) were involved in 
either private or government work which was categorized as non farmers. Thirty three women 
reported their partner’s HIV test status and 18 (54.5%) had partners who had never tested for 
HIV. The remaining 15 women (45.5%) had partners who had tested for HIV before. 
          
  Table 1: Characteristics of HIV- infected pregnant women starting ART.   
  
Factor Level 
Freq (%)     
  
Mean (+/- St.dv) 
  
Median(IQR) 
  
Year of Registration 
2009 25 (50%)   
  2010 25 (50%)   
  Age at baseline Continuous 29 (+/- 6)   
  
CD4 category 
Below 350 22 (47.8%)   
  Above 350 24 (52.2%)   
  
Start Regimen 
AZT/3TC/EFV 30 (60%)   
  AZT/3TC/NVP 3 (6%)   
  d4T/3TC/NVP 10 (20%)   
  Other 7 (14%)   
  
Baseline WHO stage 
1 41 (82%)   
  2 5 (10%)   
  3 2 (4%)   
  4 2 (4%)   
  Gestation at registration Trimester 1 14 (28.6%)   
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  Trimester 2 11 (22.4%)   
  Trimester 3 24 (49%)   
  
Parity 
No Child 11 (29.7%)   
  One & More 26 (70.3%)   
  
Disclosure 
Yes 36 (72%)   
  No 14 (28%)   
  
Marital status 
Married 32 (80%)   
  Single 8 (20%)   
  
Alcohol 
Yes 9 (18.4%)   
  No 40 (81.6%)   
  
Education 
None 5 (14.3%)   
  Primary 28 (80%)   
  Secondary 2 (5.7%)   
  
Occupation 
Farmers 31 (94%)   
  Non-farmers 2 (6%)   
  
Partner tested 
Yes 15 (45.5%)   
  No 18 (54.5%)   
          
 
Outcomes 
Adherence to ART 
No woman in this study had reported having failed to take the right amount of the antiretroviral 
drugs prescribed by the attending clinician. The findings of this study, therefore, show that 
adherence to ART for these enrolled HIV – infected pregnant women was sufficient (good) for 
all the participants during the entire period they were followed up.  
Predictors of adherence to ART 
Predictors to adherence could not be ascertained as all the HIV – infected pregnant women 
starting life-long ART reported sufficient adherence.   
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Retention in care 
Although the absolute numbers suggest a difference in retention during pregnancy and during 
two years after delivery, statistical evidence shows that retention in care was similar for these 
two periods. Although our sample size was small, the log rank test for comparison of retention 
showed statistical evidence of no difference between these two periods (P = 0.491). Thirty (30) 
of the 50 HIV – infected pregnant women starting life-long ART included in the study were still 
in care by 2 years since registration into the cohort. Thus, twenty women (40%) were lost to 
follow up by 2 years since their registration into the cohort. Among these women not retained in 
HIV care, 14 (70%) were lost during the period after pregnancy and 6 women (30%) lost during 
pregnancy as seen in figure 2 below.  
Figure 3 shows Kaplan Meier estimates of retention in care both during pregnancy and after 
pregnancy. The log rank test for the comparison between the two periods showed no evidence of 
a difference in retention between the two periods. The analysis involved taking follow up time 
into consideration.  
The incidence rates of non retention during pregnancy were 47 per 1,000 person months of 
follow up while after pregnancy incidence was 18 per 1,000 person months of follow up. The HR 
for non retention were reduced by half after pregnancy compared to during pregnancy although 
this evidence was not statistically significant (HR: 0.5, 95%CI: 0.07-3.57). 
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Figure 3: Females not retained in care and periods when they were lost from care. 
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Figure 4: Kaplan Meier estimates of retention in care during and after pregnancy. 
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Predictors of retention in care 
Baseline CD4 cell counts and the type of ART regimen started showed statistically significant 
associations with retention in care (P=0.016 and P=0.022 respectively).  
Among women with CD4 cell counts below 350cells/mm3, 81.3% were still in care by 2 years 
while 18.7% of them were not retained. Among the women with CD4 cell counts above 
350cells/mm3, 45.8% were still in care by 2 years while 54.2% were not retained. At univariable 
Cox regression, there was statistical evidence that CD4 cell counts significantly predict retention 
in care among HIV-infected pregnant women. Women with CD4 cell counts above 
350cells/mm3 were three times more likely to be lost compared to those with CD4 cell counts 
below 350cells/mm3 (HR: 3.16, 95% CI: 1.00-9.97 P= 0.049). However, after adjusting for 
other variables in multivariable Cox regression and given the small sample size, there was no 
statistical evidence that CD4 cell counts predicted retention in HIV care among these women 
starting life-long treatment (HR: 3.12, 95% CI: 0.3-31.86 P= 0.34).  
Among women initiated on AZT/3TC/EFV regimen, 53.3% were lost while 46.7% were still in 
care by two years. Women initiated on regimens including; AZT/3TC/NVP, d4T/3TC/NVP and 
other combination ART, 80% were still in care and 20% lost during the study period. Initiation 
on ART regimens other than AZT/3TC/EFV, made women 64% more likely to stay in care but 
this evidence was only marginally significant at univariable Cox regression (HR: 0.36, 95% CI: 
0.12-1.09 P= 0.073). When other variables were adjusted for in multivariable Cox regression, 
there was no evidence that the type of regimen started predicted retention in HIV care among 
women (HR: 1.4, 95% CI: 0.12-15.74 P= 0.784). 
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There was only marginal statistical evidence (P= 0.062) of association between retention in care 
and the gestational trimester of the woman at the time of registration. So was the association 
between the woman’s school education level and retention in care (P= 0.067). 
Women that were registered into the cohort while in the last trimester of their pregnancy were 
almost three times more likely to be lost from care as compared to women registered while in 
their first or second trimester. However, there was only marginal statistical evidence to support 
this finding on univariable Cox regression analysis (HR: 2.56, 95% CI: 0.96-6.84 P= 0.061). 
When other variables were adjusted for in multivariable Cox regression, there was no evidence 
that the trimester at registration predicted retention (HR: 4.17, 95% CI: 0.41-41.92 P= 0.225). 
There was marginal statistical evidence that women with any school education compared to 
those with no level of school education, were less likely to get lost to follow up (HR: 0.24, 95% 
CI: 0.06-1.03 P= 0.055). Upon adjusting for other variables in the multiple variable Cox 
regression model, this effect lost significance (HR: 1.01, 95% CI: 0.06-17.74 P= 0.996). 
There was no statistical evidence to support any associations between retention in care and all 
the other factors studied; age at baseline (P=0.468), year of registration (P=0.564),  baseline 
WHO stage (P=0.724),  number of children the woman had (P=0.695), distance to clinic 
(P=0.734),  disclosure of HIV status (P=0.797),  marital status (P=0.677), alcohol use (P=0.720),  
occupation(P=1.000),  and knowing the partner’s HIV test (P=0.722) as noted in the table 2 
below. 
Table 3 shows all univariable and multivariable Cox regression analyses and the hazard ratios 
generated. 
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Table 2: Bivariable analysis of factors associated with retention in care 
among HIV infected pregnant women starting ART. 
  
  
Factor Level 
Lost Still in care 
P-value 
  
  
Freq (%) Freq (%) 
  
Mean(St.dv) Mean(St.dv) 
  Age at baseline Continuous 28 (+/- 7) 29 (+/- 5) 0.4608*   
  
CD4 category 
Below 350 4 (18.2%) 18 (81.8%) 
0.016# 
  
  Above 350 13 (54.2%) 11 (45.8%)   
  Year of 
Registration 
2009 11 (44%) 14 (56%) 
0.564¶ 
  
  2010 9 (36%) 16 (64%)   
  
Start Regimen 
AZT/3TC/EFV 16 (53.3%) 14 (46.7%) 
0.022# 
  
  Other regimens 4 (20%) 16 (80%)   
  Baseline WHO 
stage 
Stage 1 17 (41.5%) 24 (58.5%) 
0.724# 
  
  Other stages 3 (33.3%) 6 (66.7%)   
  Gestation at 
registration 
Trimester 1&2 7 (28%) 18 (72%) 
0.062¶ 
  
  Trimester 3 13 (54.2%) 11 (45.8%)   
  
Parity 
No Child 2 (18.2%) 9 (81.8%) 
0.695# 
  
  One/more 7 (26.9%) 19 (73.1%)   
  
Disclosure 
Yes 14 (38.9%) 22 (61.1%) 
0.797¶ 
  
  No 6 (42.9%) 8 (57.1%)   
  
Marital status 
Married 9 (28.1%) 23 (71.9%) 
0.677# 
  
  Single 3 (37.5%) 5 (62.5%)   
  
Alcohol 
Yes 4 (44.4%) 5 (55.6%) 
0.72# 
  
  No 15 (37.5%) 25 (62.5%)   
  
Education 
None 3 (60%) 2 (40%) 
0.067# 
  
  Any 5 (16.7%) 25 (83.3%)   
  
Occupation 
Farmers 7 (22.6%) 24 (77.4%) 
1# 
  
  Non-farmers 0 (0.00%) 2 (100%)   
  
Distance to clinic 
less than 5km 4 (28.6%) 10 (71.4%) 
0.734# 
  
 
More than 5km 10 (37%) 17 (63%) 
   
Partner tested 
Yes 4 (26.7%) 11 (73.3%) 
0.722# 
  
  No 6 (33.3%) 12 (66.7%)   
¶ ( Pearson's Chi square test ) * (ttest ) # (Fisher's exact test) 
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Table 3: Univariable and Multivariable analysis of factors associated with retention in care 
among HIV infected pregnant women starting ART. 
  
  
Factor Level 
UNIVARIABLE ANAYSIS 
MULTIVARIABLE 
ANAYSIS 
  
  Un-
adjusted 
HR 
Confid 
Interval 
P value 
Adjust
ed HR 
Confid 
Interval 
P 
value 
  
    
  Age at baseline Continuous 0.94 0.87 1.03 0.205         
  
CD4 category 
Below 350 Base 
  
Base 
  
  
  Above 350 3.16 1.00 9.97 0.049 * 3.12 0.3  31.86 0.34   
  
Start Regimen 
AZT/3TC/EFV Base 
  
Base 
  
  
  
Other 
regimens 
0.36 0.12 1.09 0.073 * 1.4 0.12  15.74 0.784   
  Gestation at 
registration 
Trimester 1&2 Base 
  
Base 
  
  
  Trimester 3 2.56 0.96  6.84 0.061 * 4.17 0.41  41.92 0.225   
  
Education 
None Base     Base       
  Any 0.24 0.06  1.03 0.055 * 1.01 0.06  17.74 0.996   
  Baseline WHO 
stage 
Stage 1 Base             
  Other stages 0.82 0.24  2.84 0.756         
  * Included in the final multivariable model   
 
Time to non retention 
Total follow up time from all women included in the study was 901 person months for the entire 
study period. Women that were retained in care by two years contributed 730 person months of 
follow up time while those that were not retained contributed 171 person months.   
Women that were not retained in care both during and after pregnancy had a median follow up of 
9 months and IQR [1.5-13] months. Hence, time to non retention as generated by this data was 
approximately 9 months since registration in the cohort. 
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Figure 5: Kaplan Meier estimates of time to non retention in care 
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Chapter Four: Discussion 
Introduction 
This chapter explains the findings of our study with key comparison to other close studies 
elsewhere. Each finding is assessed in detail with the outcomes studied and related to existing 
literature attaching careful relevance to public health value of HIV clinical care of the pregnant 
women starting ART. It ends with the limitations that we faced during the study. 
Discussion 
Our research aimed at establishing the difference in adherence to ART and retention in care, 
during pregnancy and after pregnancy including the predictive factors to these two outcomes. We 
also assessed the median time (in months) to non retention. The study was among HIV-infected 
pregnant women starting life-long treatment at Ifakara between 2009 and 2010. They were 
followed for two years to 2011 and 2012 respectively. 
 Our findings show that adherence was sufficient (good) for all women as long as they 
participated in the study. Although there was no statistical evidence to show differences in 
retention in care between the two periods, absolute numbers retained were more during 
pregnancy than after pregnancy. None of the clinical and socio-demographic factors studied 
independently predicted retention in care or adherence to ART. Median time to non retention 
was 9 months upon registration with an IQR of 1.5-13 months. 
The above summary of results is discussed below per stated study objective with comparison to 
results from other studies. 
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Adherence to ART 
Adherence to ART was sufficient (good) for all the HIV-infected pregnant women in the study. 
Contrary to what is seen elsewhere [23, 25, 35]all participants reported 100% adherence. None 
of them had adherence reported as insufficient (poor) in the dataset. We believe this was so 
because the CDCI thoroughly counsels the women before they are started on ART. This could be 
a good practice that other programs might want to adopt. This result could also have arisen due 
to reporting bias since we used patient self report to assess this outcome. This bias could not be 
dealt with since our data was secondary. Otherwise, other ways of assessment including 
unannounced home pill count [33]and plasma drug concentrations could have offered a better 
option. Fortunately, PSR has been seen not to differ much from these two other measurements of 
adherence [32, 33]. The presence of viral load counts for these women would have been a perfect 
proxy for adherence in this population for comparison with the PSR as was done in another study 
[14].  
The need to understand adherence trends in this population cannot be over emphasized as the 
benefits to sufficient (good) adherence to ART during pregnancy and postpartum are enormous 
including improved livelihoods and good PMTCT outcomes [13, 14, 24]. A finding with 
differences in adherences between the two periods for our group would have provided a 
background for a better understanding of which period (during pregnancy or afterwards) HIV-
infected pregnant women starting ART are at risk of insufficient (poor) adherence.  
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Predictors of Adherence to ART 
The fact that all women had sufficient adherence to ART for both periods compared, we were 
unable to tease out how the studied socio-economic, demographic and clinical factors predicted 
adherence to ART. Stigma, poverty and successfully protecting the baby had been seen 
elsewhere [23, 27] as predictors but our dataset didn’t have them recorded.  
Retention in care 
Retention in care was similar when compared between the two periods during pregnancy and 
after pregnancy. However absolute numbers showed more people getting lost to follow up after 
pregnancy than during pregnancy. This could have been due to the longer follow up period after 
pregnancy. Women were followed up until two years since the day of registration yet most of 
them were registered in their second and third trimester which means their follow up time while 
pregnant was approximately six months for the majority allowing for over fourteen months of 
follow up after pregnancy.  
Taking follow up time into consideration, incidence rates of loss to follow up during pregnancy 
were 47 per 1,000 person months of follow up while after pregnancy incidence was 18 per 1,000 
person months. This trend suggests that loss to follow up is reduced by almost half if a woman 
was kept into care until delivery.  
Although not many studies exist that have assessed retention in care among HIV – infected 
pregnant women starting ART, one done in South Africa recently [31] has findings different 
from the ones we got in our study. Women that tested HIV positive during pregnancy in the 
South African study, those eligible to start ART had 40% non retention.  
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Among women that were not eligible, 22% were lost. Including pregnant women that were both 
eligible to start ART and not eligible put general non retention levels at about 50% for this 
population. 
Predictors of retention in care 
We didn’t find any independent predictors of retention in care among the factors studied. This 
could have been due to the smaller sample of participants we registered that may not have been 
significant in the multivariable models run. However, when univariable models were run, the 
trend was that women with CD4 cell counts above 350cells/mm3 at registration had higher 
hazards of non retention in care than their counterparts who got registered with CD4 cell counts 
less than 350cells/mm3. This finding suggests that sicker HIV – infected pregnant women at 
registration (as depicted by lower CD4 counts) tend to stay in care more compared to those that 
don’t feel that sick at registration. This same finding has been shown in other studies across 
Africa looking at both eligible and non-eligible for ART female populations [28, 35-37]. 
Similarly, more women initiated on AZT/3TC/EFV were lost to follow up compared to women 
initiated on other regimens. Much as it could have been due to the larger numbers on this 
regimen, it is also likely that side effects due to EFV could have accounted for the losses. Our 
study didn’t capture side effects to the drugs initiated. 
Women that were registered into the cohort while in the last trimester of their pregnancy were 
almost three times more likely to be lost from care as compared to women registered while in 
their first or second trimester. Likewise, women with any education compared to those with no 
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level of education, were less likely to get lost to follow up. These findings were consistent with 
what was found elsewhere [31, 37] 
Time to non retention 
Among women not retained in care over the 2 year period of follow up, the median time to non 
retention was 9 months. In our review of available studies, none mentions time to non retention 
among HIV – infected pregnant women starting life-long ART. Considering that majority of the 
women are registered in their second or third trimester, this puts the danger period to non-
retention at about six months after the baby is born. This could however have been affected by 
our small sample size. 
Limitations 
While considering the findings of this study we acknowledge the fact that the dataset used was 
from only one HIV care and treatment center. This sample may not be representative of the vast 
numbers of HIV-infected pregnant women starting ART.  Other sites might have a completely 
different experience and hence the need to do such studies elsewhere. Our study design was 
secondary data analysis and hence limited in the scope of factors to study. The ones included 
were those that had been collected during that study period. For future research, prospective 
studies should be designed to include and measure all factors exhaustively. 
The findings of the study need a cautious interpretation due to the small sample size. Even 
though we included everyone who met the eligibility criteria, the number of study participants 
remained small. We were also unable to rule out mortality and transfers among those considered 
lost and this might have led to a slight increase in estimation of the outcome.  
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Chapter Five: Conclusions and Recommendations 
Introduction 
This chapter has conclusions based on the evidence generated and comparison with other studies 
as discussed earlier. It ends with the recommendations plus suggested further research to answer 
more questions generated out of this study. 
Conclusions  
Our findings demonstrate that overall, adherence to ART was more than 95% while retention in 
care was 60%. Retention in care was similar for the 2 periods when HIV-infected pregnant 
women starting life-long ART were pregnant and after pregnancy. Adherence to ART was 
sufficient throughout the follow up period. This delivers more hope for the Option B+ program. 
It also reassures those countries that have rolled out and many that are still rolling out this 
program. We can have some confidence that these women started on ART during pregnancy will 
stay in care.  
There were no independent predictors of retention in care among the factors studied in this study. 
However, we believe implementing programs need to assess critically women; 
 With CD4 cell counts above 350 cells/mm3  
 Registered in late pregnancy  
 With no education, for aggressive counseling to attain a better public health outcome and 
clinical benefit to the women starting ART in pregnancy. 
 Student No: 737395                                                                                                                                       Page 38 
 
The study also found that after registration into care, the HIV-infected women who start life-long 
ART will have a median time to non retention in care of about 9 months since registration. Our 
sample size could have had an effect on the results we got and thus recommend bigger numbers 
in further studies as put below. 
Recommendations 
Since we worked with just one care and treatment centre, we recommend that similar studies be 
done elsewhere with bigger sample sizes to compare outcomes for different locations. The larger 
sample sizes would give more conclusive results regarding adherence to ART and retention in 
care among HIV-infected women starting ART in pregnancy. 
Involvement of local leadership and other partners is needed to send pregnant women to care and 
treatment centers before late pregnancy. This will ensure more women coming into care early 
and increasing the chances of retaining them into care.  The impact on public health outcome 
will increase since being in care will result in taking their prescribed ART and preventing HIV 
infection to their sexual partners and babies in the forthcoming pregnancies. 
We also recommend that for this population, counseling on the importance of staying retained in 
HIV care be emphasized at ANCs. This would mitigate the losses from care seen a few months 
after giving birth. 
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Appendices  
Appendix One: University ethics approval 
Approval from the ethics committee (medical) of the University of the Witwatersrand 
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Appendix Two: Permission to use dataset by Ifakara Health Institute 
Permission from the Ifakara Health Institute head to use the dataset. 
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